Q1 Earnings Roundup: PacBio (NASDAQ:PACB) And The Rest Of The Life Sciences Tools & Services Segment

June 04, 2025 at 23:31 PM EDT

PACB Cover Image

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at life sciences tools & services stocks, starting with PacBio (NASDAQ: PACB).

The life sciences tools and services sector supports the research, development, and commercialization of biotechnology and pharmaceutical products. These companies offer a broad range of tools, from lab consumables and testing equipment to data analytics platforms and clinical trial support. There is recurring revenue potential from long-term contracts, high margins from specialized products, and the growing demand for precision medicine and data-driven insights. However, challenges include dependence on research and development budgets from large pharmaceutical companies and the boom and bust nature of smaller biotech companies. Looking forward, the life sciences tools and services sector is expected to benefit from strong tailwinds, including advancements in genomics and the rising focus on personalized medicine. Ongoing adoption of artificial intelligence in research and drug discovery, along with the growing need for regulatory compliance and data analytics, should provide longer-term demand support. However, headwinds such as the uncertainty around healthcare and research funding as well as pricing pressures from cost-conscious customers may feed into uncertainty in the sector.

The 21 life sciences tools & services stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 3.3% while next quarter’s revenue guidance was 0.5% above.

In light of this news, share prices of the companies have held steady as they are up 1.9% on average since the latest earnings results.

PacBio (NASDAQ: PACB)

Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ: PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness.

PacBio reported revenues of $37.15 million, down 4.3% year on year. This print exceeded analysts’ expectations by 5.2%. Overall, it was a stunning quarter for the company with a solid beat of analysts’ EPS estimates.

“We are off to a solid start to the year, highlighted by a full quarter of shipments of the Vega platform, record consumables revenue and improved non-GAAP gross margin,” said Christian Henry, President and Chief Executive Officer.

The stock is down 14.3% since reporting and currently trades at $1.02.

Is now the time to buy PacBio? Access our full analysis of the earnings results here, it’s free.

Best Q1: UFP Technologies (NASDAQ: UFPT)

With expertise dating back to 1963 in specialized materials and precision manufacturing, UFP Technologies (NASDAQ: UFPT) designs and manufactures custom solutions for medical devices, sterile packaging, and other highly engineered products for healthcare and industrial applications.

UFP Technologies reported revenues of $148.1 million, up 41.1% year on year, outperforming analysts’ expectations by 5.9%. The business had an incredible quarter with a solid beat of analysts’ EPS estimates.

UFP Technologies pulled off the fastest revenue growth among its peers. The market seems happy with the results as the stock is up 21.8% since reporting. It currently trades at $240.08.

Is now the time to buy UFP Technologies? Access our full analysis of the earnings results here, it’s free.

Weakest Q1: Avantor (NYSE: AVTR)

With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE: AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries.

Avantor reported revenues of $1.58 billion, down 5.9% year on year, falling short of analysts’ expectations by 1.6%. It was a softer quarter as it posted a miss of analysts’ organic revenue and EPS estimates.

Avantor delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 14% since the results and currently trades at $13.31.

Read our full analysis of Avantor’s results here.

Medpace (NASDAQ: MEDP)

Founded in 1992 as a scientifically-driven alternative to traditional contract research organizations, Medpace (NASDAQ: MEDP) provides outsourced clinical trial management and research services to help pharmaceutical, biotechnology, and medical device companies develop new treatments.

Medpace reported revenues of $558.6 million, up 9.3% year on year. This print surpassed analysts’ expectations by 6%. Overall, it was an exceptional quarter as it also logged an impressive beat of analysts’ organic revenue and EPS estimates.

The stock is up 8.5% since reporting and currently trades at $312.74.

Read our full, actionable report on Medpace here, it’s free.

Fortrea (NASDAQ: FTRE)

Spun off from Labcorp in 2023 to focus exclusively on clinical research services, Fortrea (NASDAQ: FTRE) is a contract research organization that helps pharmaceutical, biotech, and medical device companies develop and bring their products to market through clinical trials and support services.

Fortrea reported revenues of $651.3 million, down 1.6% year on year. This number beat analysts’ expectations by 7.1%. It was an exceptional quarter as it also put up a solid beat of analysts’ EPS estimates and full-year EBITDA guidance beating analysts’ expectations.

The stock is down 15.7% since reporting and currently trades at $5.19.

Read our full, actionable report on Fortrea here, it’s free.

Market Update

Thanks to the Fed’s series of rate hikes in 2022 and 2023, inflation has cooled significantly from its post-pandemic highs, drawing closer to the 2% goal. This disinflation has occurred without severely impacting economic growth, suggesting the success of a soft landing. The stock market thrived in 2024, spurred by recent rate cuts (0.5% in September and 0.25% in November), and a notable surge followed Donald Trump’s presidential election win in November, propelling indices to historic highs. Nonetheless, the outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. The path forward holds both optimism and caution as new policies take shape.

Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

About Us

About Cabling Installation & Maintenance

Contact Cabling Installation & Maintenance

Editorial

Advertising and Sponsorship Sales

Subscriptions and Memberships

Feedback/Problems